Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C54H88O18 |
Molecular Weight | 1025.2657 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 26 / 26 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(C[C@H](O)[C@H](O)[C@H](C)O1)O[C@@H]2C[C@@](O)(O[C@H](C)[C@H]2CC)[C@@H](C)[C@H](O)[C@H](C)[C@@]3([H])OC(=O)\C=C\C=C\[C@H](C)[C@]([H])(OC(=O)\C=C\C=C\[C@@H]3C)[C@@H](C)[C@@H](O)[C@H](C)[C@@]4(O)C[C@@H](O[C@@]5([H])C[C@H](O)[C@H](O)[C@H](C)O5)[C@H](CC)[C@@H](C)O4
InChI
InChIKey=OSERMIPXNLXAPD-MJMYBOKFSA-N
InChI=1S/C54H88O18/c1-13-37-33(9)71-53(63,25-41(37)67-45-23-39(55)49(61)35(11)65-45)31(7)47(59)29(5)51-27(3)19-15-17-22-44(58)70-52(28(4)20-16-18-21-43(57)69-51)30(6)48(60)32(8)54(64)26-42(38(14-2)34(10)72-54)68-46-24-40(56)50(62)36(12)66-46/h15-22,27-42,45-52,55-56,59-64H,13-14,23-26H2,1-12H3/b19-15+,20-16+,21-18+,22-17+/t27-,28-,29-,30-,31-,32-,33+,34+,35-,36-,37+,38+,39-,40-,41+,42+,45-,46-,47+,48+,49+,50+,51-,52-,53+,54+/m0/s1
Elaiophylin (also known as Azalomycin-B) is a natural compound, a macrolide antibiotic that was first isolated from a culture of Streptomyces melanosporus. Elaiophylin is a novel and potent inhibitor of late-stage autophagy with outstanding antitumor activity in human ovarian cancer cells. In addition was shown, that elaiophylin could be a promising therapeutic strategy for overcoming incurable multiple myeloma (MM), even when TP53 mutations are present. It is known, that autophagy inhibition is a promising approach and is being investigated as a new target strategy for ovarian cancer treatment. Autophagy, a lysosome-dependent pathway, is a complex catabolic process that involves the degradation of dysfunctional or useless cytoplasmic constituents. Thus, elaiophylin, a novel autophagy inhibitor with unique chemical structure, provides the potential for structure-based development of autophagy inhibitors for new cancer therapies. Also, elaiophylin is an inhibitor of a testosterone 5 alpha-reductase.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0006914 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25893854 |
|||
Target ID: CHEMBL2363075 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10344572 |
5.8 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25893854
in mice: SKOV3 cells resuspended injected subcutaneously in to the flanks of 4-wk-old BALB/C athymic mice. When mice exhibited palp able tumors, they were randomly assigned to treatment groups (6 to 8 mice per group) to avoid treatment bias. Elaiophylin (Azalomycin-B) was given i.p. (1 or 2mg/kg) every2 d for 21 d, or DMSO was used as a control. After the initial treatment, the tumor size was determined every day.
Route of Administration:
Intraperitoneal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25893854
Autophagic flux was inhibited by elaiophylin treatment. Increased numbers of autophagosomes can be associated either with increased autophagosome synthesis or decreased autophagosome turnover. To distinguish between these 2 possibilities, there were measured the autophagic flux. First, was analyzed autophagy in the presence of autophagy inhibitors, such as 3-methyladenine (3-MA) and chloroquine (CQ) in GFP-LC3B-SKOV3 cells. Coincubation of elaiophylin (0.5 μM) with 3-MA (10 mM), which blocked the upstream steps of autophagy, reduced the accumulation of (GFP)-tagged microtubule-associated protein 1 light chain 3 β (LC3B) (GFP-LC3B). puncta. In contrast, coincubation of elaiophylin (0.5 μM) with CQ (25 μM), which blocked the downstream steps of autophagy, did not induce a significant increase in GFP-LC3B puncta compared with elaiophylin treatment alone, indicating that elaiophylin was not an autophagy inducer. Additionally, elaiophylin-treated cells did not exhibit an increase in LC3B-II levels in CQ-treated cells compared with control cells.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
77879
Created by
admin on Sat Dec 16 02:08:25 GMT 2023 , Edited by admin on Sat Dec 16 02:08:25 GMT 2023
|
PRIMARY | |||
|
37318-06-2
Created by
admin on Sat Dec 16 02:08:25 GMT 2023 , Edited by admin on Sat Dec 16 02:08:25 GMT 2023
|
PRIMARY | |||
|
6444206
Created by
admin on Sat Dec 16 02:08:25 GMT 2023 , Edited by admin on Sat Dec 16 02:08:25 GMT 2023
|
PRIMARY | |||
|
DTXSID001318254
Created by
admin on Sat Dec 16 02:08:25 GMT 2023 , Edited by admin on Sat Dec 16 02:08:25 GMT 2023
|
PRIMARY | |||
|
1CAF8865TM
Created by
admin on Sat Dec 16 02:08:25 GMT 2023 , Edited by admin on Sat Dec 16 02:08:25 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD